| 000 | 04791cam a2200853 i 4500 | ||
|---|---|---|---|
| 001 | 1266258710 | ||
| 003 | OCoLC | ||
| 005 | 20220525103634.0 | ||
| 008 | 220302s2022 nyuaf b 000 0 eng | ||
| 010 | _a2022001763 | ||
| 020 | _a9780063210790 | ||
| 020 | _a0063210797 | ||
| 035 |
_a(OCoLC)1266258710 _z(OCoLC)1252411451 _z(OCoLC)1273586219 _z(OCoLC)1286848313 _z(OCoLC)1291404130 _z(OCoLC)1296034824 _z(OCoLC)1301513438 |
||
| 037 |
_bHarpercollins, 53 Glenmaura National Blvd Ste 300, Moosaic, PA, USA, 18507-2132 _nSAN 200-2086 |
||
| 040 | _cAJM | ||
| 042 | _apcc | ||
| 100 | 1 |
_aBourla, Albert, _eauthor. _911162 |
|
| 245 | 1 | 0 |
_aMoonshot : _binside Pfizer's nine-month race to make the impossible possible / _cDr. Albert Bourla. |
| 246 | 3 | _aInside Pfizer's nine-month race to make the impossible possible | |
| 246 | 3 | _aInside Pfizer's 9-month race to make the impossible possible | |
| 250 | _aFirst edition. | ||
| 264 | 1 |
_aNew York, NY : _bHarper Business, an imprint of HarperCollinsPublishers, _c[2022] |
|
| 300 |
_axix, 216 pages, 8 unnumbered pages of plates : _billustrations (some color) ; _c24 cm |
||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_aunmediated _bn _2rdamedia |
||
| 338 |
_avolume _bnc _2rdacarrier |
||
| 504 | _aIncludes bibliographical references (pages [197]-214). | ||
| 505 | 0 | _aPreface: Luck never comes to the unprepared -- Business NOT as usual -- What is obvious is not always right -- Thinking big makes the impossible possible -- Lightspeed -- The ultimate joy -- Past, present, future -- Manufacturing, the second miracle -- Equity : easier said than done -- Navigating a political minefield -- A beacon of hope -- The science of trust -- A pro-patient, pro-innovation agenda -- Epilogue -- Acknowledgments -- Appendix: Albert Bourla's "we stand with science" open letter to colleagues. | |
| 520 |
_a"The exclusive, first-hand, behind-the-scenes story of how Pfizer raced to create the first Covid-19 vaccine, told by Pfizer's CEO Dr. Albert Bourla"-- _cProvided by publisher. |
||
| 520 | _a"A riveting, fast-paced, inside look at one of the most incredible private sector achievements in history, Moonshot recounts the intensive nine months in 2020 when the scientists at Pfizer, under the visionary leadership of Dr. Albert Bourla, made "the impossible possible"--creating, testing, and manufacturing a safe and effective Covid-19 vaccine that previously would have taken years to develop." -- inside front book jacket flap. | ||
| 600 | 1 | 0 |
_aBourla, Albert. _911162 |
| 610 | 2 | 0 |
_aPfizer Inc. _911163 |
| 610 | 2 | 7 |
_aPfizer Inc. _2fast _0(OCoLC)fst00532911 _911163 |
| 647 | 7 |
_2fast _0(OCoLC)fst02024716 |
|
| 650 | 0 |
_aDrug development _xHistory. _911164 |
|
| 650 | 0 |
_aCOVID-19 (Disease) _xVaccination. _911165 |
|
| 650 | 0 |
_aViral vaccines _xBiotechnology. _911166 |
|
| 650 | 0 |
_aViral vaccines. _911167 |
|
| 650 | 0 |
_aVaccines industry. _911168 |
|
| 650 | 0 |
_aImmunology. _911192 |
|
| 650 | 0 |
_aBiotechnology. _911193 |
|
| 650 | 0 |
_aCOVID-19 (Disease) _xPrevention. _911194 |
|
| 650 | 0 |
_aCOVID-19 Pandemic, 2020- _911195 |
|
| 650 | 0 |
_aCOVID-19 vaccines _xHistory. _911196 |
|
| 650 | 0 |
_amRNA vaccines _xHistory. _911197 |
|
| 650 | 2 |
_aViral Vaccines _911167 |
|
| 650 | 2 |
_aAllergy and Immunology _911198 |
|
| 650 | 2 |
_aBiotechnology _911193 |
|
| 650 | 6 |
_aMédicaments _xDéveloppement _xHistoire. _911199 |
|
| 650 | 6 |
_aCOVID-19 _xVaccination. _911200 |
|
| 650 | 6 |
_aVaccins antiviraux _xBiotechnologie. _911201 |
|
| 650 | 6 |
_aVaccins antiviraux. _911202 |
|
| 650 | 6 |
_aVaccins _xIndustrie. _911203 |
|
| 650 | 6 |
_aImmunologie. _911204 |
|
| 650 | 6 |
_aBiotechnologie. _911183 |
|
| 650 | 6 |
_aPandémie de COVID-19, 2020- _911184 |
|
| 650 | 7 |
_abioengineering. _2aat _911185 |
|
| 650 | 7 |
_aBUSINESS & ECONOMICS / Industries / Pharmaceutical & Biotechnology. _2bisacsh _911186 |
|
| 650 | 7 |
_aMEDICAL / Immunology. _2bisacsh _911187 |
|
| 650 | 7 |
_aBUSINESS & ECONOMICS / Research & Development. _2bisacsh _911188 |
|
| 650 | 7 |
_aBiotechnology. _2fast _0(OCoLC)fst00832729 _911193 |
|
| 650 | 7 |
_aCOVID-19 (Disease) _xPrevention. _2fast _0(OCoLC)fst02021842 _911194 |
|
| 650 | 7 |
_aCOVID-19 (Disease) _xVaccination. _2fast _0(OCoLC)fst02021881 _911165 |
|
| 650 | 7 |
_aDrug development. _2fast _0(OCoLC)fst00898670 _911189 |
|
| 650 | 7 |
_aImmunology. _2fast _0(OCoLC)fst00968006 _911192 |
|
| 650 | 7 |
_aVaccines industry. _2fast _0(OCoLC)fst01163593 _911168 |
|
| 650 | 7 |
_aViral vaccines. _2fast _0(OCoLC)fst01167621 _911167 |
|
| 650 | 7 |
_aViral vaccines _xResearch. _2fast _0(OCoLC)fst01167622 _911190 |
|
| 650 | 7 |
_aCOVID-19 (Disease) _2sears _911191 |
|
| 655 | 7 |
_aHistory. _2fast _0(OCoLC)fst01411628 _949 |
|
| 776 | 0 | 8 |
_iOnline version: _aBourla, Dr. Albert. _tMoonshot _dNew York : Harper Business, 2022 _z9780063210820 _w(DLC) 2022001764 |
| 907 | _a.b173089355 | ||
| 942 |
_2ddc _cBOOK |
||
| 999 |
_c28254 _d28254 |
||